Novartis adds Indianapolis site to its manufacturing capacity for radioligand drug Pluvicto

No­var­tis has the go-ahead from the FDA to man­u­fac­ture its ra­dio­phar­ma­ceu­ti­cal Plu­vic­to at a new fa­cil­i­ty in In­di­anapo­lis, mark­ing a step to­ward ad­dress­ing bur­geon­ing de­mand.

The Big Phar­ma’s new 70,000-square-foot fa­cil­i­ty is spe­cial­ly de­signed to make ra­di­oli­gand ther­a­pies (RLTs) and, ac­cord­ing to the com­pa­ny, is the largest No­var­tis site of its kind. The fa­cil­i­ty has space for con­tin­ued line ex­pan­sion, in­clud­ing plans for ful­ly au­to­mat­ed lines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.